1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy;
2Center for Applied Biomedical Research (CRBA), University of Bologna, Bologna, Italy;
3IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy;
4Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy;
5Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padua, Padua, Italy;
6Division of Gastroenterology and Hepatology, Città Della Salute e Della Scienza Hospital, Turin, Italy;
7Internal Medicine, Humanitas Medical Care Catania, Catania, Italy;
8Internal Medicine, Hospital of Faenza, Azienda Unità Sanitaria Locale of Romagna, Faenza, Italy;
9Internal Medicine, Hospital of Bentivoglio, Azienda Unità Sanitaria Locale of Bologna, Bologna, Italy;
10Department of Primary Health Care, Internal Medicine Unit Addressed to Frailty and Aging, “Santa Maria Delle Croci” Ravenna Hospital, AUSL Romagna, Ravenna, Italy.
Correspondence: Paolo Caraceni, MD. E-mail: [email protected].
*Giacomo Zaccherini and Maurizio Baldassarre share first authorship.
**Mauro Bernardi and Paolo Caraceni share senior authorship on this article.
‡Investigators of the Human Albumin for the Treatment of Ascites in Patients with Hepatic Cirrhosis (ANSWER) Trial are listed in the Supplementary Appendix.
SUPPLEMENTARY MATERIAL accompanies this paper at https://links.lww.com/AJG/C679
